To all our Stakeholders,
Roivant Sciences has acquired the global rights to PA101 — our Ph 2b candidate for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. As PA101 was our only drug candidate, Patara Pharma has terminated operations concurrent with this transaction. We are excited that a drug candidate invented by us will be robustly developed by Roivant, which maximizes the probability this important new therapy will be approved for patients in the shortest amount of time.
Bill, Ahmet, and Pravin – Patara Pharma co-founders